Vor Bio Announces Publication of Interim Analysis of TELIGAN, a China Phase 3 Trial of Telitacicept in IgA Nephropathy, in The New England Journal of Medicine

Rhea-AI Summary

Vor Bio (Nasdaq: VOR) reported interim Phase 3 TELIGAN data for telitacicept in IgA nephropathy from a China trial published in NEJM.

Telitacicept achieved a 58.9% UPCR reduction vs 8.8% for placebo at week 39, with stable eGFR, favorable kidney outcomes, and generally consistent safety.

Positive

• Primary endpoint met: 58.9% UPCR reduction vs 8.8% placebo, 55.0% relative difference (p<0.001)
• Kidney function stable: eGFR -1.0% vs -7.7% placebo at week 39
• Lower ≥30% eGFR decline: 6.3% telitacicept vs 27.0% placebo
• Higher proteinuria response: 61.0% vs 19.5% achieved UPCR below 0.8 at week 39
• Consistent proteinuria reductions across prespecified patient subgroups
• Serious adverse events less frequent: 2.5% telitacicept vs 8.2% placebo

Negative

• Most common telitacicept adverse events: upper respiratory tract infection and injection-site reactions
• Treatment associated with reductions in immunoglobulin levels, including 60.6% mean serum IgA decrease

News Market Reaction – VOR

-5.28%

4 alerts

-5.28% Session close to close

$819.29M Market Cap

0.1x Rel. Volume

In the May 14 session, VOR declined 5.28%, reflecting a notable negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.3% in the session following this news. A negative reaction despite strong TELIGAN...

Analysis

The stock moved -5.3% in the session following this news. A negative reaction despite strong TELIGAN results fits prior patterns where positive telitacicept data sometimes coincided with weak stock performance, with similar clinical headlines averaging -1.46% next-day moves. The market has previously faded NEJM publications and Phase 3 wins, potentially reflecting concerns about execution, capital needs, or existing resale registrations, even while the underlying clinical profile appeared favorable.

Key Figures

Proteinuria reduction: 55.0% relative reduction vs placebo UPCR reduction (drug): 58.9% reduction from baseline UPCR reduction (placebo): 8.8% reduction from baseline +5 more

8 metrics

Proteinuria reduction 55.0% relative reduction vs placebo Interim Phase 3 TELIGAN, week 39 primary endpoint

UPCR reduction (drug) 58.9% reduction from baseline 24-hour UPCR at week 39 with telitacicept

UPCR reduction (placebo) 8.8% reduction from baseline 24-hour UPCR at week 39 with placebo

eGFR change -1.0% vs -7.7% Mean percentage change from baseline at week 39 (drug vs placebo)

eGFR ≥30% decline 6.3% vs 27.0% Patients with confirmed ≥30% eGFR decline (drug vs placebo)

UPCR <0.8 responders 61.0% vs 19.5% Patients achieving UPCR below 0.8 at week 39 (drug vs placebo)

Serum IgA reduction 60.6% mean reduction Change in serum IgA levels with telitacicept

Serious adverse events 2.5% vs 8.2% Serious AEs in telitacicept vs placebo groups

Previous Clinical trial Reports

5 past events · Latest: Mar 30 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 30	Phase 3 trial start	Positive	+1.5%	First patient dosed in global Phase 3 UPSTREAM SjD trial of telitacicept.
Nov 08	Phase 3 IgAN data	Positive	+0.5%	Phase 3 IgA nephropathy Stage A met primary endpoint with strong proteinuria reduction.
Oct 29	gMG extension data	Positive	-5.3%	48-week open-label extension in generalized myasthenia gravis showed sustained efficacy and safety.
Oct 17	IgAN presentation news	Positive	-0.2%	Late-breaking ASN presentation announced for China Phase 3 IgA nephropathy study results.
Oct 16	SLE NEJM publication	Positive	-3.8%	NEJM publication of China Phase 3 telitacicept trial in systemic lupus erythematosus.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical trial announcements for telitacicept have often been positive scientifically but have shown mixed and sometimes negative next-day price reactions.

Recent Company History

Over the past year, Vor Bio has repeatedly reported positive Phase 3 data and updates for telitacicept across multiple autoimmune indications, including Sjögren’s disease, IgA nephropathy, generalized myasthenia gravis, and systemic lupus erythematosus. Despite generally favorable efficacy and safety signals, market reactions have ranged from modest gains (e.g., +1.52% on Mar 30, 2026) to noticeable declines (e.g., -5.29% on Oct 29, 2025), suggesting investor responses to clinical news have been inconsistent.

Key Terms

IgA nephropathy, BAFF, APRIL, UPCR, +3 more

7 terms

IgA nephropathy medical

"Phase 3 TELIGAN trial evaluating telitacicept in IgA nephropathy in China"

A kidney disease caused when deposits of the antibody called IgA collect in the tiny filters of the kidney, gradually reducing their ability to clear waste — like grit building up in a water filter. It matters to investors because it creates demand for diagnostics, drugs and long‑term care, drives clinical trial activity and regulatory decisions, and can influence the financial outlook of companies in pharma, biotech, medical devices and health insurance.

BAFF medical

"best-in-class dual BAFF/APRIL therapy across autoimmune diseases"

BAFF is a naturally occurring protein that helps certain immune cells (B cells) grow, survive and produce antibodies; think of it as a fertilizer that encourages those cells to multiply. It matters to investors because drugs that block or enhance BAFF can change the course of autoimmune diseases or B‑cell cancers, so clinical results, approvals or partnerships tied to BAFF-related therapies can strongly affect a biotech company’s value and prospects.

APRIL medical

"best-in-class dual BAFF/APRIL therapy across autoimmune diseases"

April is the fourth month of the year and the first month of the second calendar quarter for most businesses. For investors, April often marks the transition from one reporting period to the next—companies close their first-quarter books and many issue quarterly results or guidance—so it can signal fresh information that affects stock prices, much like a school report card that helps parents reassess progress and expectations.

UPCR medical

"24-hour urinary protein-to-creatinine ratio (UPCR), compared with an 8.8% reduction"

UPCR (urine protein-to-creatinine ratio) is a lab measure that compares the amount of protein to creatinine in a single urine sample to estimate how much protein the kidneys are leaking each day. For investors, shifts in UPCR reported in clinical trials or drug safety data act like a dashboard warning for kidney health, and can strongly affect a therapy’s clinical success, regulatory chances, and commercial prospects.

CD19+ B cells medical

"associated with reductions in circulating CD19+ B cells and serum"

CD19+ B cells are a group of immune cells (B lymphocytes) identified by a specific protein, CD19, on their surface—think of CD19 as a name tag that lets doctors and researchers find and count these cells. They matter to investors because changes in their number or function are used as markers of how well B-cell‑targeting drugs, vaccines or immune therapies are working and can signal safety or efficacy issues that affect a company’s clinical and commercial prospects.

immunoglobulin medical

"and serum immunoglobulin levels, including a 60.6% mean reduction"

Immunoglobulins are proteins commonly known as antibodies that the body makes to recognize and neutralize viruses, bacteria and other foreign substances; they act like targeted security guards that bind to specific invaders. For investors, immunoglobulins matter because they are the basis for many diagnostic tests, therapeutic drugs and blood‑derived products, so changes in demand, manufacturing capacity, clinical trial results or regulatory approvals can directly affect company revenues and risk profiles.

placebo-controlled medical

"randomized, double-blind, placebo-controlled trial conducted at 72 sites in China"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Interim analysis demonstrated a 55.0% relative reduction in proteinuria versus placebo at 39 weeks with eGFR remaining stable through treatment 

Results further support the potential for telitacicept to become a best-in-class dual BAFF/APRIL therapy across autoimmune diseases

BOSTON, May 14, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that results from the Phase 3 TELIGAN trial evaluating telitacicept in IgA nephropathy in China sponsored by its collaborator, RemeGen Co., Ltd., (HKEX: 9995, SHA: 688331), were published in The New England Journal of Medicine (NEJM).

“We are honored to see the TELIGAN interim analysis published in The New England Journal of Medicine, which we believe speaks to the rigor of the trial and adds to the growing body of evidence supporting the potential of telitacicept across autoimmune diseases,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio. “In IgA nephropathy, telitacicept demonstrated substantial reductions in proteinuria together with encouraging preservation of kidney function, with eGFR remaining largely stable through 39 weeks while declining in the placebo arm. We believe these results are encouraging in the context of the evolving treatment landscape for IgA nephropathy. More broadly, as data continue to emerge across multiple B-cell mediated diseases, we believe telitacicept has the potential to become a best-in-class dual BAFF/APRIL therapy capable of delivering meaningful benefit for patients globally.”

The publication reports results from a prespecified interim analysis of the ongoing Phase 3 TELIGAN trial, a multicenter, randomized, double-blind, placebo-controlled trial conducted at 72 sites in China evaluating telitacicept in adults with biopsy-proven IgA nephropathy and persistent proteinuria despite optimized supportive care.

The study met its primary endpoint, demonstrating a statistically significant reduction in proteinuria at week 39. Patients treated with telitacicept achieved a 58.9% reduction from baseline in 24-hour urinary protein-to-creatinine ratio (UPCR), compared with an 8.8% reduction for placebo, representing a 55.0% relative difference between groups (p<0.001). Treatment effects emerged as early as week 4, with separation from placebo widening through week 39.

Additional findings from the interim analysis included:

• Kidney function preservation: Estimated glomerular filtration rate (eGFR) remained stable with telitacicept, with a mean percentage change from baseline of -1.0% compared with -7.7% for placebo at week 39.
• Reduced risk of kidney function decline: A confirmed decline in eGFR of ≥30% occurred in 6.3% of telitacicept-treated patients compared with 27.0% of placebo-treated patients.
• Proteinuria response: At week 39, 61.0% of telitacicept-treated patients achieved a UPCR below 0.8 compared with 19.5% of placebo-treated patients.
• Broadly consistent activity across subgroups: Reductions in proteinuria were observed consistently across prespecified patient subgroups, including baseline kidney function, proteinuria level, and use of SGLT2 inhibitors.
• Pharmacodynamic activity: Telitacicept treatment was associated with reductions in circulating CD19+ B cells and serum immunoglobulin levels, including a 60.6% mean reduction in serum IgA levels.
  
  

Safety findings were generally consistent with previous studies of telitacicept. Most adverse events were mild to moderate in severity. Serious adverse events occurred less frequently with telitacicept than placebo (2.5% vs. 8.2%). The most common adverse events associated with telitacicept included upper respiratory tract infection, injection-site reactions, and reductions in immunoglobulin levels.

About Telitacicept
Telitacicept is a novel recombinant fusion protein designed to treat autoimmune diseases through dual inhibition of BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology.

Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). Additional regulatory filings in China are underway, including biologics license applications for primary Sjögren’s disease (SjD) and IgA nephropathy (IgAN).

Vor Bio is advancing telitacicept in global Phase 3 trials in gMG and SjD to support potential regulatory approvals in the United States, Europe, and Japan.

About IgA Nephropathy
IgA nephropathy (IgAN) is one of the most common primary glomerular diseases worldwide and a leading cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD). It is characterized by IgA-containing immune complex deposition in the kidney, leading to inflammation, proteinuria, hypertension, and progressive loss of renal function. Up to 40% of patients progress to ESRD within 20 years of diagnosis, underscoring the significant unmet need for effective therapies. Current treatment approaches, including optimized blood pressure control, renin-angiotensin system blockade, and SGLT2 inhibitors, primarily slow disease progression but do not address the underlying immunopathology.

The prevailing scientific consensus is that overproduction of galactose-deficient IgA1 (Gd-IgA1) is a central driver of IgAN. BAFF and APRIL, two cytokines critical to B-cell survival and function, promote the production of Gd-IgA1 and its pathogenic antibodies.

About Vor Bio
Vor Bio is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a novel dual-target fusion protein, through Phase 3 clinical development and potential commercialization to address serious autoantibody-driven conditions worldwide. For more information visit www.vorbio.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “aim,” “anticipate,” “can,” “continue,” “could,” “design,” “enable,” “expect,” “initiate,” “intend,” “may,” “on-track,” “ongoing,” “plan,” “potential,” “should,” “target,” “update,” “will,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include Vor Bio’s statements regarding the potential for telitacicept to become a best-in-class dual BAFF/APRIL therapy across autoimmune diseases and to deliver meaningful benefit for patients globally; Vor Bio’s development and commercialization plans for telitacicept; and other statements that are not historical fact.

Vor Bio may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various factors, including the data for our product candidates may not be sufficient for obtaining regulatory approval to commercialize products; we may not be able to execute our business plans, including meeting our planned clinical and regulatory milestones and timelines, and possible limitations of financial and other resources. The results of the clinical trial described in this press release are based on information reported by RemeGen; Vor Bio has not independently verified this data. These and other risks are described in greater detail under the caption “Risk Factors” included in Vor Bio’s most recent annual or quarterly report and in other reports it has filed or may file with the Securities and Exchange Commission.

Any forward-looking statements contained in this press release speak only as of the date hereof, and Vor Bio expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as may be required by law.

Media & Investor Contacts:
Carl Mauch
cmauch@vorbio.com

FAQ

What did Vor Bio (VOR) announce about the TELIGAN Phase 3 trial interim analysis?

Vor Bio announced positive interim Phase 3 TELIGAN results for telitacicept in IgA nephropathy, published in The New England Journal of Medicine. According to Vor Bio, the study met its primary endpoint with significant proteinuria reduction and maintained kidney function compared with placebo at 39 weeks.

How effective was telitacicept in reducing proteinuria in the TELIGAN IgA nephropathy trial (VOR)?

Telitacicept showed a 58.9% reduction from baseline in 24-hour UPCR versus 8.8% for placebo at week 39. According to Vor Bio, this represents a 55.0% relative difference between groups with treatment effects emerging by week 4 and widening through week 39.

What impact did telitacicept have on kidney function (eGFR) in the TELIGAN Phase 3 trial for VOR?

Telitacicept maintained largely stable kidney function, with mean eGFR change of -1.0% versus -7.7% for placebo at week 39. According to Vor Bio, confirmed ≥30% eGFR decline occurred in 6.3% of telitacicept patients compared with 27.0% on placebo.

What were the safety results for telitacicept in the TELIGAN IgA nephropathy trial for Vor Bio (VOR)?

Safety findings were generally consistent with previous telitacicept studies, with most adverse events mild to moderate. According to Vor Bio, serious adverse events occurred less often with telitacicept (2.5%) than placebo (8.2%), with common events including upper respiratory infections and injection-site reactions.

How many telitacicept-treated patients achieved low proteinuria levels in the TELIGAN Phase 3 trial (VOR)?

At week 39, 61.0% of telitacicept-treated patients reached a UPCR below 0.8 versus 19.5% on placebo. According to Vor Bio, reductions in proteinuria were consistent across prespecified subgroups, including baseline kidney function, proteinuria level, and SGLT2 inhibitor use.

What pharmacodynamic effects of telitacicept were observed in Vor Bio’s TELIGAN study (VOR)?

Telitacicept was associated with reductions in circulating CD19+ B cells and serum immunoglobulin levels. According to Vor Bio, this included a 60.6% mean reduction in serum IgA levels, supporting its mechanism as a dual BAFF/APRIL-targeting therapy in B-cell mediated autoimmune diseases.

Why is the NEJM publication of the TELIGAN telitacicept data important for Vor Bio (VOR) investors?

Publication in The New England Journal of Medicine highlights peer-reviewed recognition of TELIGAN’s Phase 3 interim results. According to Vor Bio, the data add to evidence for telitacicept in IgA nephropathy and other B-cell mediated autoimmune diseases, potentially supporting future development and partnerships.